Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is set to present new preclinical data on its TNX-801 vaccine candidate at the upcoming Vaccine Congress 2025 in Vienna. The presentation, scheduled for July 10, will be delivered by Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development at Tonix. TNX-801, a recombinant horsepox virus live vaccine, has demonstrated protective efficacy against mpox and other orthopoxviruses in animal models following a single dose. This development is significant as it represents a potential advancement in the fight against mpox, a disease that has seen outbreaks globally, and other related viruses.
The TNX-801 platform is designed to elicit durable immune responses, which could be crucial for long-term protection against mpox and other emerging viral threats. Dr. Bavari's presentation will cover key findings on the safety, immunogenicity, and efficacy of TNX-801, along with the company's plans to move forward with clinical trials. The ability of TNX-801 to provide protection with a single dose could simplify vaccination campaigns and improve public health responses to outbreaks.
Tonix Pharmaceuticals is a biopharmaceutical company with a focus on addressing public health challenges, including infectious diseases and pain management. The company's efforts to develop TNX-801 are part of a broader strategy to modernize solutions for emerging health threats. With the potential to initiate clinical trials, the presentation at Vaccine Congress 2025 marks a critical step in the development of TNX-801 and its possible future role in global health.
For more information on Tonix Pharmaceuticals and its research, visit https://www.TonixPharma.com.
